<DOC>
	<DOC>NCT02117297</DOC>
	<brief_summary>Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.</brief_summary>
	<brief_title>SCT Plus Immune Therapy in Average Risk AML/MDS</brief_title>
	<detailed_description>Reduced intensity conditioning regimen of Busulfan (Bu) and Fludarabine (Flu) + Anti-Thymocyte Globulin (ATG ) (unrelated donors only) or reduced toxicity conditioning regimen of Bu/Flu/alemtuzumab, or reduced hepatic toxicity regimen of melphan/Flu/alemtuzumab and AlloSCT, followed by Gemtuzumab Ozogamicin consolidation in patients with average risk AML/MDS meeting eligibility criteria.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Disease Status: AML 1st CR with a matched family donor AML 1st CR with unrelated donor AML 2nd CR or CRP MDS and &lt; or = 5% bone marrow myeloblasts at diagnosis Disease Immunophenotype: Disease must express a minimum of &gt; or = 10% CD33 positivity for patients with AML Organ Function: Adequate renal function, adequate liver function, adequate cardiac function, adequate pulmonary function Patients with active CNS AML disease at time of preparative regimen Secondary MDS Poor cytogenetics Female patients who are pregnant Karnofsky &lt;70% or Lansky &lt;50% if 10 years or less Age &gt;30 years Seropositive for HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>